1
|
Liu Z, Xie J, Gao X, Lin Y, Sun M, Sun Y, Peng D, Xie H, Li X, Li Z, Cai T, Chen P, Wu Z, Guo S, Li Y, Zhang Z, Qin Z, Han H, He Z, Liu J, Fu W, Li S, Xia D, Wang X, Deng C, Xu Z, Zhou F, Yao K, Yu W, Ye Y, Liu Z. SAVE Testis-sparing score: a multicenter retrospective study of a novel predictive tool for quantifying testicular tumors. Int J Surg 2023; 109:4185-4198. [PMID: 37738014 PMCID: PMC10720877 DOI: 10.1097/js9.0000000000000752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 08/29/2023] [Indexed: 09/23/2023]
Abstract
BACKGROUND Testis-sparing surgery (TSS) is a safe treatment for patients with benign testicular tumors. Presently, assessments for evaluating the suitability of TSS are poorly standardized, partially because testicular anatomical elements cannot be quantitatively described. MATERIALS AND METHODS The authors developed a scoring method known as the SAVE testis-sparing score based on four critical and accessible anatomical features of a testicular tumor. The SAVE score ranges from 0 to 8 and is divided into four risk classes ( low , medium , high , and extremely high ) to evaluate the feasibility of TSS, wherein low-risk indicates high feasibility and vice versa. This study included 444 testicular tumor patients from eight centers. Among them, 216 patients (model group: 151 patients, validation group: 65 patients) were included in the modeling analysis, and the other 228 patients from children's centers were included in the proportion analysis. Using retrospective data, patient characteristics associated with surgical methods were identified. Furthermore, a multivariate logistic regression model was built quantify the associations between these characteristics and the surgery method. The receiver operator characteristic curve was used to evaluate the classification efficiency of SAVE. RESULTS The SAVE testis-sparing score includes size (tumor size as maximal diameter), available testicular tissue volume, volume ratio of the tumor to the testis, and the exophytic / endophytic properties of the tumor. The SAVE scoring system accurately classified the suitability of TSS based on the complexity of benign testicular tumors. CONCLUSION The SAVE score is a reproducible and robust tool for quantitatively describing the anatomical characteristics of benign testicular tumors and guide the preoperative evaluation of TSS.
Collapse
Affiliation(s)
- Zhenhua Liu
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Junyi Xie
- Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center, Beijing
| | - Xiaofeng Gao
- Department of Pediatric Urology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health
| | - Yuan Lin
- Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
| | - Mengkui Sun
- Department of Urology, Shenzhen Children’s Hospital, Shenzhen, Guangdong Province
| | - Yubo Sun
- Department of Pediatric Urology, Children’s Hospital of Fudan University, Shanghai
| | - Ding Peng
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province
| | - Haibiao Xie
- Department of Urology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou
| | - Xiangdong Li
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Zhiyong Li
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Taonong Cai
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Pengyu Chen
- Department of Urology, Shenzhen Children’s Hospital, Shenzhen, Guangdong Province
| | - Zhiming Wu
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Shengjie Guo
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Yonghong Li
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Zhilin Zhang
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Zike Qin
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Hui Han
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Zhisong He
- Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center, Beijing
| | - Jiumin Liu
- Department of Urology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou
| | - Wen Fu
- Department of Pediatric Urology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health
| | - Shoulin Li
- Department of Urology, Shenzhen Children’s Hospital, Shenzhen, Guangdong Province
| | - Dan Xia
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province
| | - Xiang Wang
- Department of Pediatric Urology, Children’s Hospital of Fudan University, Shanghai
| | | | - Zhe Xu
- Department of Pediatric Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province
| | - Fangjian Zhou
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Kai Yao
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Wei Yu
- Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center, Beijing
| | - Yunlin Ye
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
| | - Zhuowei Liu
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou
- Department of Urology, Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou, Gansu Province, People’s Republic of China
| |
Collapse
|